# HexAgon研究第二期部分的中期結果顯示，接受INBRX-106組合治療的患者中有44%達成確定的客觀反應，而對照組為21.4%。

*biotech · news · 2026-05-11 · Benzinga*

## Key points

- INBRX-106組合達成44%的客觀反應率，對照組為21.4%。
- 在第二期試驗中，INBRX-106組有三名患者達成完全放射學反應。
- Inhibrx將於2026年第三季啟動INBRX-106的第三期臨床試驗。
- INBRX-106的圍手術期非小細胞肺癌研究將於本季稍晚開始。
- Inhibrx計劃測試INBRX-106與疫苗、T細胞接合劑及CAR-T療法的組合。

Combination Therapy Shows Deeper Tumor Reduction The interim results from the Phase 2 portion of the HexAgon study showed that 44% of patients receiving the INBRX-106 combination achieved a confirmed objective response, compared to 21.4% in the control group. The data represent a significant increase in confirmed responses, highlighting the potential of INBRX-106 as a treatment option. Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response. Inhibrx Expands INBRX-106 Development Pipeline The company expects progression-free survival data from the Phase 2 portion of the HexAgon study in the fourth quarter of 2026 and plans to start the Phase 3 portion in the third quarter of 2026. The clinical-stage biopharmaceutical company also plans to expand evaluation of INBRX-106 into broader indications aimed at improving checkpoint inhibitor efficacy. A perioperative non-small cell lung cancer study is expected to begin later this quarter, reflecting the company's view that OX40 agonism may offer the strongest curative potential in earlier-stage disease, where immune systems remain more responsive. The company is also preparing to move into first-line metastatic NSCLC, with studies targeted to begin in 2027. Company Plans Additional Combination Studies Beyond checkpoint inhibitor combinations, it plans to evaluate INBRX-106 alongside therapies that may benefit from T-cell costimulation, including vaccines, T-cell engagers, and CAR-T therapies. INBX Stock Price Activity: Inhibrx Biosciences shares were up 3.95% at $139.66 at the time of publication on Monday, according to Benzinga Pro data. Photo via Shutterstock

**Companies:** Inhibrx

[Read the full story on Benzinga](https://www.benzinga.com/trading-ideas/movers/26/05/52462244/inhibrx-cancer-treatment-shows-high-response-rates-in-head-and-neck-cancer-study)

---

Canonical: https://newsio.io/zh-TW/n/b226e459-c053-47e9-9463-3e0b341d3105/hexagoninbrx-1064421-4
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works